1. **Question:** Can you tell us when ADE measures might be included in mandatory reporting via MIPS or other payments?

**Answer:** According to the draft 2018 MIPS measures table, CMS does not have Adverse Drug Event (ADE) measures available for reporting for the Calendar Year 2018 performance period. About three years ago, the Physician Quality Reporting System (PQRS) did have an ADE Warfarin measure under consideration for implementation. It was analyzed for claims implementation. Due to its use of Medicare Part D claims data, CMS was not able to implement it. For the purposes of MIPS non-electronic clinical quality measures, CMS utilizes Medicare Part B claims data and usually not Medicare Part D claims data. Mathematica Policy Research (MPR), a contractor to CMS, is developing the ADE Eligible Clinician (EC) electronic Clinical Quality Measure (eCQM) described below.

Three divisions at CMS have provided a short summary of their ADE measures: Division of Chronic and Post-Acute Care (DCPAC) measures:
* Drug regimen review (process measure that attempts to prevent adverse drug events)
* Readmissions and Potentially Preventable Readmission (PPR) measures include ADEs in the numerator.

Division of Quality Measurement (DQM) Hospital/Ambulatory Surgery Center (ASC) measures:
* Readmission and complication measures include ADEs in the numerator
* A pregnancy ADE measure is under development.

Division of Electronic and Clinician Quality (DECQ) MIPS measures:
* No current ADE measures in MIPS or from Qualified Clinical Data Registries (QCDRs)
* EC eCQM under development: Adverse Drug Events for Patients Taking Anticoagulant Medications in an Ambulatory Setting

2. **Question:** Does a 10% reduction in outpatient hypoglycemic episodes refer to the number of episodes, the duration of individual episodes, or an aggregate time under hypoglycemia?

**Answer:** The 10% reduction refers to the rate of emergency department visits for adverse drug events due to diabetes agents; the numerator estimate is the number of emergency department visits for adverse drug events from insulin, and the denominator estimate is the number of patients receiving dispensed insulin in US retail outpatient settings. Please visit [https://health.gov/hcq/ade-measures.asp](https://health.gov/hcq/ade-measures.asp) for further details about the outpatient measures.

3. **Question:** For the inpatient measures, what does "adverse events" include for each of the numerators?
Answer: Contact Noel Eldridge at the Agency for Health Care Research and Quality for (noel.eldridge@ahrq.hhs.gov). He has a brief 6 slide set which provides details on the MPSMS anticoagulant and hypoglycemic agent adverse events.

4. **Question:** Is the National Targets and Measures for ADE Reductions available for downloading? Currently, the only one online is the 2014 Prevention version.

   **Answer:** The webpage that describes the information presented on this webinar on the National Targets and Measures is available on our Health.gov page. Click in the Health Care Quality and Patient Safety section, and look in the “adverse drug event” tab. [https://health.gov/hcq/ade-measures.asp](https://health.gov/hcq/ade-measures.asp)

5. **Question:** What is CMS doing about anticoagulants? When will the ICD-10 validation work be completed for bleeding events?

   **Answer:** Data collection is nearing completion, with results available in 2018.